Spinocerebellar ataxia type 30

Spinocerebellar ataxia type 30 (SCA30) is a rare, slowly progressive autosomal dominant cerebellar ataxia that primarily affects the cerebellum and its connections. It was first identified in an Australian family of Anglo-Celtic origin. The disease is characterized by a relatively pure cerebellar syndrome, meaning it predominantly affects cerebellar function without significant involvement of other neurological systems, although some patients may develop mild additional features over time. The hallmark symptoms of SCA30 include slowly progressive gait ataxia (unsteadiness when walking), limb ataxia, dysarthria (slurred or poorly coordinated speech), and nystagmus or other oculomotor abnormalities. Cerebellar atrophy is typically observed on brain imaging (MRI). The onset of symptoms generally occurs in adulthood, often in the fourth to sixth decade of life, though age of onset can vary. The progression of the disease tends to be slow, and many affected individuals retain the ability to walk for many years after symptom onset. The genetic locus for SCA30 has been mapped to chromosome 4q34.3-q35.1, but the specific causative gene has not yet been definitively identified. There is currently no cure or disease-modifying treatment for SCA30. Management is supportive and symptomatic, including physical therapy to maintain mobility and balance, speech therapy for dysarthria, and occupational therapy to assist with daily activities. Regular neurological follow-up is recommended to monitor disease progression.

Common questions about Spinocerebellar ataxia type 30